Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Modified Release Hydrocortisone (Chronocort) in Healthy Volunteers
NCT02408068Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Curve from time 0 to last measurable concentration at 24 hours and 4 more. Started Jan 2015; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)adrenal insufficiency (AI)
Beyond the preview
Go deeper on NCT02408068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408068.